Research progress of diabetic heart disease

Home > Archive>Volume 28, Issue 8, 2020 >679-687

Research progress of diabetic heart disease
DOI:
                        
                    
CSTR:
                        [cstr]
                    
Author:
                        QIU JunlinQIU Junlin
Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LUO ShuomingLUO Shuoming
Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHOU ZhiguangZHOU Zhiguang
Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China)
Clc Number:R54
Fund Project:

Article

Figures

Metrics

Reference [98]

Related [20]

Cited by

Materials

Comments

Abstract:

The incidence rate of diabetes has increased dramatically in recent years, becoming another major disease next to cardiovascular and cerebrovascular diseases and cancer, and seriously endangering human health. Diabetic heart disease is the most serious in diabetes, with extremely high mortality. Diabetes affects the heart in three ways:coronary artery disease, diabetic cardiomyopathy, and cardiac autonomic neuropathy. Different types of diabetes have different incidence. The pathogenesis of the three types of diabetic heart disease has something in common, but the means of screening and treatment are different. This review integrates the latest developments related to the mechanism, clinical screening and potential therapeutic approaches of diabetic heart disease.

Key words:diabetic heart disease; coronary artery disease; diabetic cardiomyopathy; cardiac autonomic neuropathy; type 1 diabetes mellitus; type 2 diabetes mellitus

Reference

[1] Chaib F.New WHO statistics highlight increases in blood pressure and diabetes, other noncommunicable risk factors.Cent Eur J Public Health, 2,0(2):134-149.

[2] Paneni F, Beckman JA, Creager MA, et al.Diabetes and vascular disease:pathophysiology, clinical consequences, and medical therapy:part I.Eur Heart J, 3,4(31):2436-2443.

[3] Morrish NJ, Wang SL, Stevens LK, et al.Mortality and causes of death in the WHO multinational study of vascular disease in diabetes.Diabetologia, 1,4(Suppl 2):S14-S21.

[4] Palumbo PJ, Elveback LR, Chu CP, et al.Diabetes mellitus:incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970.Diabetes, 6,5(7):566-573.

[5] Rawshani A, Rawshani A, Sattar N, et al.Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus.Circulation, 9,9(16):1900-1912.

[6] Nathan DM, DCCT/EDIC Research Group.The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years:overview.Diabetes Care, 4,7(1):9-16.

[7] Gerstein HC, Shah R.Cardiovascular outcomes trials of glucose-lowering drugs or strategies in type 2 diabetes.Endocrinol Metab Clin North Am, 8,7(1):97-116.

[8] Rawshani A, Rawshani A, Franzen S, et al.Mortality and cardiovascular disease in type 1 and type 2 diabetes.N Engl J Med, 7,6(15):1407-1418.

[9] Lind M, Bounias I, Olsson M, et al.Glycaemic control and incidence of heart failure in 0,5 patients with type 1 diabetes:an observational study.Lancet, 1,8(9786):140-146.

[10] Brunvand L, Fugelseth D, Stensaeth KH, et al.Early reduced myocardial diastolic function in children and adolescents with type 1 diabetes mellitus a population-based study.BMC Cardiovasc Disord, 6,6:103.

[11] Iribarren C, Karter AJ, Go AS, et al.Glycemic control and heart failure among adult patients with diabetes.Circulation, 1,3(22):2668-2673.

[12] Stratton IM, Adler AI, Neil HA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study.BMJ, 0,1(7258):405-412.

[13] Dimitropoulos G, Tahrani AA, Stevens MJ.Cardiac autonomic neuropathy in patients with diabetes mellitus.World J Diabetes, 4,5(1):17-39.

[14] Maser R, Lenhard M, DeCherney G.Cardiovascular autonomic neuropathy:the clinical significance of its determination.Endocrinologist, 0,0:27-33.

[15] Spallone V, Ziegler D, Freeman R, et al.Cardiovascular autonomic neuropathy in diabetes:clinical impact, assessment, diagnosis, and management.Diabetes Metab Res Rev, 1,7(7):639-653.

[16] Balcioglu AS, Müderrisoglu H.Diabetes and cardiac autonomic neuropathy:Clinical manifestations, cardiovascular consequences, diagnosis and treatment.World J Diabetes, 5,6(1):80-91.

[17] Andrzej B.Cardiac autonomic neuropathy:Why should cardiologists care about that?.J Diabetes Res, 7,7:1-9.

[18] Pop-Busui R.Cardiac autonomic neuropathy in diabetes.Diabetes Care, 0,3(2):434-441.

[19] Vinik AI, Erbas T.Diabetic autonomic neuropathy.Semin Neurol, 3,3(4):365-372.

[20] Yahagi K, Kolodgie FD, Lutter C, et al.Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus.Arterioscler Thromb Vasc Biol, 7,7(2):191-204.

[21] Yahagi K, Davis HR, Arbustini E, et al.Sex differences in coronary artery disease:Pathological observations.Atherosclerosis, 5,9(1):260-267.

[22] Moreno PR, Murcia AM, Palacios IF, et al.Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus.Circulation, 0,2(18):2180-2184.

[23] Lanzer P, Boehm M, Sorribas V, et al.Medial vascular calcification revisited:review and perspectives.Eur Heart J, 4,5(23):1515-1525.

[24] Olson JC, Edmundowicz D, Becker DJ, et al.Coronary calcium in adults with type 1 diabetes:a stronger correlate of clinical coronary artery disease in men than in women.Diabetes, 0,9(9):1571-1578.

[25] Sheng Z, Zhou P, Liu C, et al.Relationships of coronary culprit-plaque characteristics with duration of diabetes mellitus in acute myocardial infarction:an intravascular optical coherence tomography study.Cardiovasc Diabetol, 9,8(1):136.

[26] Sezer M, Kocaaga M, Aslanger E, et al.Bimodal pattern of coronary microvascular involvement in diabetes mellitus.J Am Heart Assoc, 6,5(11):e003995.

[27] El-Asrar MA, Andrawes NG, Ismail EA, et al.Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus:relation to carotid intima media thickness.Vasc Med, 5,0(6):509-517.

[28] Adameova A, Dhalla NS.Role of microangiopathy in diabetic cardiomyopathy.Heart Fail Rev, 4,9(1):25-33.

[29] Blaha MJ, DeFilippis AP, Rivera JJ, et al.The relationship between insulin resistance and incidence and progression of coronary artery calcification:the Multi-Ethnic Study of Atherosclerosis (MESA).Diabetes Care, 1,4(3):749-751.

[30] Olesen P, Nguyen K, Wogensen L, et al.Calcification of human vascular smooth muscle cells:associations with osteoprotegerin expression and acceleration by high-dose insulin.Am J Physiol Heart Circ Physiol, 7,2(2):H1058-H1064.

[31] Lee WS, Kim J.Diabetic cardiomyopathy:Where we are and where we are going.Korean J Intern Med, 7,2(3):404-421.

[32] Jia G, Whaley-Connell A, Sowers JR.Diabetic cardiomyopathy:a hyperglycaemia- and insulin-resistance-induced heart disease.Diabetologia, 8,1(1):21-28.

[33] Jia G, DeMarco VG, Sowers JR.Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.Nat Rev Endocrinol, 6,2(3):144-153.

[34] Lazo M, Halushka MK, Shen L, et al.Soluble receptor for advanced glycation end products and the risk for incident heart failure:The Atherosclerosis Risk in Communities Study.Am Heart J, 5,0(5):961-967.

[35] Marciniak SJ, Ron D.Endoplasmic reticulum stress signaling in disease.Physiol Rev, 6,6(4):1133-1149.

[36] Falcao-Pires I, Leite-Moreira AF.Diabetic cardiomyopathy:understanding the molecular and cellular basis to progress in diagnosis and treatment.Heart Fail Rev, 2,7(3):325-344.

[37] Di Carli MF, Bianco-Batlles D, Landa ME, et al.Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus.Circulation, 9,0(8):813-819.

[38] Erbas T, Erbas B, Kabakci G, et al.Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus.Clin Cardiol, 0,3(4):259-263.

[39] Kumar R, Yong QC, Thomas CM, et al.Intracardiac intracellular angiotensin system in diabetes.Am J Physiol Regul Integr Comp Physiol, 2,2(5):R510-R517.

[40] Kurdi M, Booz GW.New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.Hypertension, 1,7(6):1034-1038.

[41] Frustaci A, Kajstura J, Chimenti C, et al.Myocardial cell death in human diabetes.Circ Res, 0,7(12):1123-1132.

[42] Edwards JL, Vincent AM, Cheng HT, et al.Diabetic neuropathy:mechanisms to management.Pharmacol Ther, 8,0(1):1-34.

[43] Verrotti A, Prezioso G, Scattoni R, et al.Autonomic neuropathy in diabetes mellitus.Front Endocrinol (Lausanne), 4,5:205.

[44] Polydefkis M, Griffin JW, McArthur J.New insights into diabetic polyneuropathy.JAMA, 3,0(10):1371-1376.

[45] Ziegler D, Buchholz S, Sohr C, et al.Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients.Acta Diabetol, 5,2(1):65-72.

[46] Jaiswal M, Fingerlin TE, Urbina EM, et al.Impact of glycemic control on heart rate variability in youth with type 1 diabetes:the SEARCH CVD study.Diabetes Technol Ther, 3,5(12):977-983.

[47] Shah MS, Brownlee M.Molecular and cellular mechanisms of cardiovascular disorders in diabetes.Circ Res, 6,8(11):1808-1829.

[48] Nyiraty S, Pesei F, Orosz A, et al.Cardiovascular autonomic neuropathy and glucose variability in patients with type 1 diabetes:is there an association?.Front Endocrinol (Lausanne), 8,9:174.

[49] Spallone V.Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes:What is defined, what is new, and what is unmet.Diabetes Metab J, 9,3(1):3-30.

[50] Jacoby RM, Nesto RW.Acute myocardial infarction in the diabetic patient:pathophysiology, clinical course and prognosis.J Am Coll Cardiol, 2,0(3):736-744.

[51] Patsouras A, Farmaki P, Garmpi A, et al.Screening and risk assessment of coronary artery disease in patients with type 2 diabetes:An updated review.Vivo, 9,3(4):1039-1049.

[52] Ulimoen GR, Ofstad AP, Endresen K, et al.Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--A cross-sectional study.BMC Cardiovasc Disord, 5,5(1):147.

[53] Shimabukuro M, Saito T, Higa T, et al.Risk stratification of coronary artery disease in asymptomatic diabetic subjects using multidetector computed tomography.Circ J, 5,9(11):2422-2429.

[54] Christensen RH, Scholten BJV , Hansen CS, et al.Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.Eur J Prev Cardiol, 7,4(14):1517-1524.

[55] Wu Y, He J, Sun X, et al.Carotid atherosclerosis and its relationship to coronary heart disease and stroke risk in patients with type 2 diabetes mellitus.Medicine, 7,6(39):e8151.

[56] Srinivasan MP, Kamath PK, Bhat NM, et al.Severity of coronary artery disease in type 2 diabetes mellitus:Does the timing matter?.Indian Heart J, 6,8(2):158-163.

[57] Fang ZY, Prins JB, Marwick TH.Diabetic cardiomyopathy:evidence, mechanisms, and therapeutic implications.Endocr Rev, 4,5(4):543-567.

[58] Khouri SJ, Maly GT, Suh DD, et al.A practical approach to the echocardiographic evaluation of diastolic function.J Am Soc Echocardiogr, 4,7(3):290-297.

[59] Yu CM, Sanderson JE, Marwick TH, et al.Tissue Doppler imaging a new prognosticator for cardiovascular diseases.J Am Coll Cardiol, 7,9(19):1903-1914.

[60] Miki T, Yuda S, Kouzu H, et al.Diabetic cardiomyopathy:pathophysiology and clinical features.Heart Fail Rev, 3,8(2):149-166.

[61] Gottlieb I, Macedo R, Bluemke DA, et al.Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies:current applications and future perspectives.Heart Fail Rev, 6,1(4):313-323.

[62] Rijzewijk LJ, van der Meer RW, Smit JW, et al.Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.J Am Coll Cardiol, 8,2(22):1793-1799.

[63] Paulus WJ, Tschope C, Sanderson JE, et al.How to diagnose diastolic heart failure:a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.Eur Heart J, 7,8(20):2539-2550.

[64] Guo R, Nair S.Role of microRNA in diabetic cardiomyopathy:from mechanism to intervention.Biochim Biophys Acta, 7,3(8):2070-2077.

[65] Buse JB, Ginsberg HN, Bakris GL, et al.Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement from the American Heart Association and the American Diabetes Association.Circulation, 7,5(1):114-126.

[66] Tesfaye S, Boulton AJM, Dyck PJ, et al.Diabetic neuropathies:update on definitions, diagnostic criteria, estimation of severity, and treatments.Diabetes Care, 0,3(10):2285-2293.

[67] Sammito S, Bckelmann I.Reference values for time- and frequency-domain heart rate variability measures.Heart Rhythm, 6,3(6):1309-1316.

[68] Bissinger A.Cardiac autonomic neuropathy:Why should cardiologists care about that?.J Diabetes Res, 7,7:5374176.

[69] Norhammar A, Malmberg K, Diderholm E, et al.Diabetes mellitus:the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.J Am Coll Cardiol, 4,3(4):585-591.

[70] Creager MA, Lüscher TF, Cosentino F, et al.Diabetes and vascular disease:pathophysiology, clinical consequences, and medical therapy:Part I.Circulation, 3,8(12):1527-1532.

[71] Dagenais GR, Lu J, Faxon DP, et al.Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.Circulation, 1,3(14):1492-500.

[72] Morice MC, Serruys PW, Sousa JE, et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med, 2,6(23):1773-1780.

[73] Babapulle MN, Joseph L, Bélisle P, et al.A hierarchical Bayesian Meta-analysis of randomised clinical trials of drug-eluting stents.Lancet, 4,4(9434):583-591.

[74] Bangalore S, Kumar S, Fusaro M, et al.Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus:mixed treatment comparison analysis of 2,4 patient years of follow-up from randomised trials.BMJ, 2,5:e5170.

[75] Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group.Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes:The DCCT/EDIC study 30-year follow-up.Diabetes Care, 6,9(5):686-693.

[76] Scirica BM, Bhatt DL, Braunwald E, et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N Engl J Med, 3,9(14):1317-1326.

[77] White WB, Cannon CP, Heller SR, et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med, 3,9(14):1327-1335.

[78] Green JB, Bethel MA, Armstrong PW, et al.Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.N Engl J Med, 5,3(3):232-242.

[79] Marso SP, Daniels GH, Brown-Frandsen K, et al.Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med, 6,5(4):311-322.

[80] Kumarathurai P, Anholm C, Larsen BS, et al.Effects of liraglutide on heart rate and heart rate variability:a randomized, double-blind, placebo-controlled crossover study.Diabetes Care, 7,0(1):117-124.

[81] Alzaid A.Empa's new clothes:the untold story of the Empa-Reg outcome trial.Diabetes Technol Ther, 7,9(6):324-327.

[82] Sharma AK, Srinivasan BP.Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats.Eur J Pharm Sci, 9,8(5):433-444.

[83] Aboukhoudir F, Rekik S.Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach.Int J Cardiovasc Imaging, 2,8(6):1329-1339.

[84] Chung J, Abraszewski P, Yu X, et al.Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control.J Am Coll Cardiol, 6,7(2):384-390.

[85] Zib I, Jacob AN, Lingvay I, et al.Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes.J Investig Med, 7,5(5):230-236.

[86] Xie Z, Lau K, Eby B, et al.Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice.Diabetes, 1,0(6):1770-1778.

[87] von Bibra H, St John Sutton M.Impact of diabetes on postinfarction heart failure and left ventricular remodeling.Curr Heart Fail Rep, 1,8(4):242-251.

[88] Mamas MA, Deaton C, Rutter MK, et al.Impaired glucose tolerance and insulin resistance in heart failure:underrecognized and undertreated?.J Card Fail, 0,6(9):761-768.

[89] Sacca L, Napoli R.Insulin resistance in chronic heart failure:a difficult bull to take by the horns.Nutr Metab Cardiovasc Dis, 9,9(5):303-305.

[90] Younce CW, Burmeister MA, Ayala JE.Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.Am J Physiol Cell Physiol, 3,4(6):C508-C518.

[91] Doehner W, Frenneaux M, Anker SD.Metabolic impairment in heart failure:the myocardial and systemic perspective.J Am Coll Cardiol, 4,4(13):1388-1400.

[92] Diabetes Control and Complications Trial Research Group.The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).Diabetologia, 8,1(4):416-423.

[93] Azad N, Emanuele NV, Abraira C, et al.The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM).J Diabetes Complications, 9,3(5-6):307-313.

[94] Charles M, Fleischer J, Witte DR, et al.Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes:ADDITION-Denmark, a cluster-randomised study.Diabetologia, 3,6(1):101-108.

[95] Gde P, Vedel P, Parving HH, et al.Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomised study.Lancet, 9,3(9153):617-622.

[96] Pop-Busui R, Boulton AJ, Feldman EL, et al.Diabetic neuropathy:a position statement by the American diabetes association.Diabetes Care, 7,0(1):136-154.

[97] Rodrigues GD, Gurgel JL, Goncalves TR, et al.Inspiratory muscle training improves physical performance and cardiac autonomic modulation in older women.Eur J Appl Physiol, 8,8(6):1143-1152.

[98] deSousa AFM, Medeiros AR, Benitez-Flores S, et al.Improvements in attention and cardiac autonomic modulation after a 2-weeks sprint interval training program:a fidelity approach.Front Physiol, 8,9:241.

Get Citation

QIU Junlin, LUO Shuoming, ZHOU Zhiguang. Research progress of diabetic heart disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(8):679-687.

Copy

Article Metrics

Abstract:1120
PDF: 1981
HTML: 0
Cited by: 0

History

Received:May 18,2020
Revised:May 25,2020
Adopted:
Online: July 03,2020
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code